203 results on '"Creutzberg, Carien L"'
Search Results
2. Prognostic impact and causality of age on oncological outcomes in women with endometrial cancer: a multimethod analysis of the randomised PORTEC-1, PORTEC-2, and PORTEC-3 trials
3. Age-Related Differences in Patient Preferences for Adjuvant Chemotherapy for High-Risk Endometrial Cancer
4. Molecular and Clinicopathologic Characterization of Mismatch Repair-Deficient Endometrial Carcinoma Not Related to MLH1 Promoter Hypermethylation
5. HECTOR: multimodal deep learning predicts recurrence risk in endometrial cancer.
6. Time Trends in the Treatment and Survival of 5036 Uveal Melanoma Patients in The Netherlands over a 30-Year Period
7. Predictive Factors for Toxicity After Primary Chemoradiation for Locally Advanced Cervical Cancer: A Systematic Review
8. Prognostic impact and causality of age on oncological outcomes in women with endometrial cancer: a multimethod analysis of the randomised PORTEC-1, -2 and -3 trials
9. Clinical Behavior and Molecular Landscape of Stage I p53-abnormal Low-Grade Endometrioid Endometrial Carcinomas
10. European Society of Gynaecological Oncology Guidelines for the Management of Patients with Vulvar Cancer - Update 2023
11. QPOLE: A Quick, Simple, and Cheap Alternative for POLE Sequencing in Endometrial Cancer by Multiplex Genotyping Quantitative Polymerase Chain Reaction
12. Abstract 5695: Deep learning risk prediction model of distant recurrence from H&E endometrial cancer slides
13. Data from Prognostic Integrated Image-Based Immune and Molecular Profiling in Early-Stage Endometrial Cancer
14. Data from A Transcriptionally Distinct CXCL13+CD103+CD8+ T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer
15. Data from Prognostic Integrated Image-Based Immune and Molecular Profiling in Early-Stage Endometrial Cancer
16. Supplementary Table 7 from A Transcriptionally Distinct CXCL13+CD103+CD8+ T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer
17. Supplementary Tables 1-6, 8 from A Transcriptionally Distinct CXCL13+CD103+CD8+ T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer
18. Supplementary Figures from A Transcriptionally Distinct CXCL13+CD103+CD8+ T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer
19. Supplementary Data from Prognostic Integrated Image-Based Immune and Molecular Profiling in Early-Stage Endometrial Cancer
20. Supplementary Table 7 from A Transcriptionally Distinct CXCL13+CD103+CD8+ T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer
21. Supplementary Tables 1-6, 8 from A Transcriptionally Distinct CXCL13+CD103+CD8+ T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer
22. Data from A Transcriptionally Distinct CXCL13+CD103+CD8+ T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer
23. Supplementary Figures from A Transcriptionally Distinct CXCL13+CD103+CD8+ T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer
24. Supplementary Data from Prognostic Integrated Image-Based Immune and Molecular Profiling in Early-Stage Endometrial Cancer
25. Supplementary figure 6 from POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer
26. Table S3 from Adjuvant Treatment for POLE Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues
27. Supplementary figure 1 from POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer
28. Supplementary Table S5 from Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer—Combined Analysis of the PORTEC Cohorts
29. Table S5 from Adjuvant Treatment for POLE Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues
30. Figure S1 from Adjuvant Treatment for POLE Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues
31. Supplementary figure 4 from POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer
32. Figure S2 from Adjuvant Treatment for POLE Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues
33. Supplementary table 2 from POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer
34. Figure S4 from Amplification of 1q32.1 Refines the Molecular Classification of Endometrial Carcinoma
35. Figure S2 from Amplification of 1q32.1 Refines the Molecular Classification of Endometrial Carcinoma
36. Figure S7 from Amplification of 1q32.1 Refines the Molecular Classification of Endometrial Carcinoma
37. Figure S3 from Adjuvant Treatment for POLE Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues
38. Table S1 from Adjuvant Treatment for POLE Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues
39. Table S4 from Adjuvant Treatment for POLE Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues
40. Table S2 from Adjuvant Treatment for POLE Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues
41. Figure S3 from Amplification of 1q32.1 Refines the Molecular Classification of Endometrial Carcinoma
42. Figure S1 from Amplification of 1q32.1 Refines the Molecular Classification of Endometrial Carcinoma
43. Supplementary figure 1 from POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer
44. Figure S3 from Amplification of 1q32.1 Refines the Molecular Classification of Endometrial Carcinoma
45. Supplementary figure 5 from POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer
46. Figure S6 from Amplification of 1q32.1 Refines the Molecular Classification of Endometrial Carcinoma
47. Supplementary Methods from Adjuvant Treatment for POLE Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues
48. Table S6 from Adjuvant Treatment for POLE Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues
49. Supplementary figure 2 from POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer
50. Supplementary figure 5 from POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.